Exosens Gains 2.24% and Marks +83% Over the Year, Boosted by Strong Results
Exosens shares rise by 2.24% to €66.30 in mid-afternoon trading, in a downward-trending Paris market. The CAC 40 is down 0.8% during the session at 8,049.98 points. Today's increase brings the three-month performance to over 20% and confirms the momentum initiated after the end-of-April quarterly publication.
Exosens shares are trading at €66.30, above their 50-day moving average (€63.59) and well above their 200-day moving average (€50.00). The stock is approaching the upper Bollinger band set at €69.41, without reaching it. The RSI at 49 remains neutral, indicating an upward movement without excess. The resistance at €72.90, identified several weeks ago, remains the next technical threshold above the current price. Today's movement follows the session on April 27, where the stock had already gained 2.67% following the publication of the first-quarter results.
Trajectory Aligned with 2025 Guidance
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The company confirmed at the end of April a 19.7% increase in revenue for the first quarter of 2026, reaching €122.6 million. During the 9M 2025 publication, Exosens aimed for revenue growth in the upper range of 15-20% for the fiscal year, along with an adjusted EBITDA increase in the lower range of 20-25%. The Q1 pace aligns with these goals. Among the opportunities mentioned by the company is the expansion of production capacities, expected to increase by 40% by 2027 to support demand in night vision and drone applications. The stock now shows an 83.66% increase over the year. Next event: the general assembly on May 22, 2026, followed by the half-year results on July 28.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
